Rapamycin and Alzheimer's disease: Time for a clinical trial?
Rapamycin and Alzheimer's disease: Time for a clinical trial?
复制标题
DOI：
10.1126/scitranslmed.aar4289
复制
发表时间：
2019-01-23
影响因子：
17.1
通讯作者：
Galvan, Veronica
中科院分区：
文献类型：
--
作者：
Kaeberlein, Matt;Galvan, Veronica
药物雷帕霉素对包括阿尔茨海默病小鼠模型在内的许多神经变性和衰老动物模型有有益作用。尽管有令人信服的临床前记录，但没有临床试验测试雷帕霉素或其他mTOR抑制剂对阿尔茨海默病患者的作用。我们认为应该进行这样的临床试验。
The drug rapamycin has beneficial effects in a number of animal models of neurodegeneration and aging including mouse models of Alzheimer's disease. Despite its compelling preclinical record, no clinical trials have tested rapamycin or other mTOR inhibitors in patients with Alzheimer's disease. We argue that such clinical trials should be undertaken.